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1. Introduction  
Stroke is the second leading cause of death and the primary cause of disability in humans. 
The phenomenon of ischemic tolerance perfectly describes the quote: “What does not kill 
you makes you stronger.’’ Ischemic pre- or post- conditioning is actually the strongest 
known procedure to prevent or reverse delayed neuronal death. It works specifically in 
sensitive vulnerable neuronal populations, which are represented by pyramidal neurons in 
the hippocampal CA1 region. However, tolerance is effective in other brain cell populations 
as well. Although, its nomenclature is ‘‘ischemic’’ tolerance (IT) ”, the tolerant phenotype 
can also be induced by other stimuli that lead to delayed neuronal death (intoxication). 
Recent data have proven further that this phenomenon is not only limited to application of 
sublethal stimuli before the lethal stress (preconditioning) but also that reversed 
arrangement of events, sublethal stress after lethal insult (postconditioning), are equally 
effective. Another very important term is ‘‘cross conditioning,’’ or the capability of one 
stressor to induce tolerance against another. Delayed neuronal death is the slow 
development of post-ischemic neuro-degeneration. This delay allows a therapeutic window 
of opportunity lasting 2–3 days to reverse the cellular death process. It seems therefore that 
the mechanisms of ischemic tolerance-delayed post-conditioning could be of use not only 
after ischemia but also in some other processes leading up to apoptosis.  
This paper summarizes results of experimental studies which have shown that acute in vivo 
forebrain ischemia as well as ischemic/reperfusion injury (IRI) both alter, the expression, 
function and kinetic parameters of Ca2+ transporters as well as the physical membrane 
environment. Furthermore, that IRI leads to the inhibition of mitochondrial respiratory 
complexes I and IV. Also, that conversely, ischemic preconditioning (IPC) acts at the level of 
both initiation and execution of IRI-induced mitochondrial apoptosis and activates 
inhibition of p53 translocation to mitochondria. 
Evidence is presented to show that endoplasmic reticulum (ER) is the site of complex 
processes such as calcium storage, synthesis and folding of proteins as well as cell response 
to stress. ER function is impaired in IRI which in turn induces depletion of stored calcium,  
the conserved stress responses linked with delayed neuronal death. In addition, IRI initiates 
time dependent differences in endoplasmic reticular (ER) gene expression of the key 
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unfolded protein response (UPR), or proteins at both the mRNA and protein levels. 
Moreover, gene expression of the UPR proteins is affected by pre-ischemic (IPC) treatment 
caused by the increased expression of Ca2+ binding protein, GRP 78 and transcriptional 
factor ATF6 in reperfusion times. Thus, IPC exerts a role in the attenuation of ER stress 
response, which might, in turn, be involved in the neuroprotective phenomenon of ischemic 
tolerance. Hippocampal cells respond to the IRI by the specific expression pattern of the 
secretory pathways Ca2+ pump (SPCA1) and this pattern is affected by preischemic 
challenge. IPC also incompletely suppresses lipid and protein oxidation of hippocampal 
membranes and leads to partial recovery of the ischemic-induced depression of SPCA 
activity. The data suggests a correlation of SPCA function with the role of secretory 
pathways (Golgi apparatus) in response to preischemic challenge. 
2. Ischemic stroke 
Ischemic stroke arises in humans as a consequence of a cardiac arrest, the stoppage of blood 
flow to the brain due to embolic or thrombic occlusion of arteries. Global or focal ischemia is 
very severe pathogenic event with multiple, parallel, and sequential pathogenesis. Global 
forebrain ischemia leads to selective cell death of vulnerable pyramidal neurons in the 
hippocampal CA1 region. It also leads to death of cerebral cortex neurons (layers 3, 5, and 6) 
and the dorsolateral striatum. When blood flow decreases during focal ischemia, the area 
surrounding the necrotic core of ischemia, also known as ‘‘penumbra’’ is perfused by 
collateral vessels. It also undergoes fatal apoptosis of neurons (Endres et al., 2008).  
Despite decades of intense research, no effective neuroprotective drugs are available to treat 
acute stroke or cardiac arrest. For this reason, recent attention has shifted to defining the 
brain’s own evolutionarily conserved endogenous neuroprotective mechanisms, which 
occurs in ischemic tolerance (IT) or after ischemic preconditioning (IPC). IT induced by 
several paradigms represents an important phenomenon of the central nervous system 
(CNS) including adaptation to sublethal short-term ischemia. This results in increased 
tolerance of CNS to lethal ischemia (Kirino, 2002; Dirnagl et al., 2003; Gidday, 2006). The 
molecular mechanisms underlying IT are not yet fully understood because of its extreme 
complexity, involving  many signaling pathways and alterations in gene expression. 
Additionally, a metabolic depression has also been suggested to play an important role in IT 
(Yenari et al., 2008). 
2.1 Ischemic tolerance as a possible neuroprotective strategy 
A transient, ischemia-resistant phenotype known as “ischemic tolerance (IT)” can be 
established in brain in a rapid or delayed fashion by a preceding non-injurious 
“preconditioning” stimulus. Thus, ischemic preconditioning (IPC) as one of the inducers, 
represents a phenomenon which eventually leads to an increase in the tolerance of CNS to 
the lethal ischemia (Dirnagl et al., 2009; Obrenovitch, 2008). Initial pre-clinical studies of 
this phenomenon relied primarily on brief periods of ischemia or hypoxia as the IPC 
stimuli, but it was later realized that many other stressors, including pharmacological 
agents, are also effective. Although considerably more experimentation is needed to 
thoroughly validate the efficacy of any already identified preconditioning agent to protect 
ischemic brain, the fact that some of these agents are already clinically used implies that 
the growing enthusiasm for translational success in the field of pharmacologic pre-
conditioning may be well justified. 
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The mechanisms underlying ischemic tolerance are rather complex and not yet fully 
understood. Two windows have been identified in all multiple paradigms for IPC. One that 
represents very rapid and short-lasting post-translational changes and a second, which 
develops slowly (over days) after initial insult as a robust and long lasting transcriptional 
changes which culminate in prolonged neuroprotection (Dirnagl et al., 2009; Obrenovitch, 
2008; Yenari et al., 2008). Differences in intensity, duration, and frequency of specific 
inducer/stressor determine the spectrum of responses to noxious stimuli. In other words, 
when the stimulus is too weak to induce any response, when it is sufficient to serve as a 
tolerance trigger, or when it is too strong and harmful, resulting in apoptotic or necrotic 
damage.  
It is symptomatic that there are no clear boundaries between acquisition of tolerance and 
cellular apoptosis/necrosis (Dirnagl et al., 2009). Rodent and cell culture models serve as a 
basis for the study of the tolerance phenomenon. Mother nature presents the perfect model 
to help understand this better. In nature, we ubiquitously find adaptation to extreme 
environmental conditions, for example, the hypoxic or anoxic tolerance. Hibernation is 
another example of inherent adaptation to extreme low-blood perfusion in animals. As such, 
ischemic tolerance can be conceived as an evolutionary conserved form of cerebral plasticity 
(Dirnagl et al., 2009,). It is not surprising therefore that different animal species have 
evolved different molecular strategies to cope with anoxia and severe metabolic stress. This 
leads to the trigger of the neuroprotective tolerance state.  
A number of common mechanisms with different relevance features can be recognized 
(Lehotsky et al., 2009b): 
- depression of metabolic rate, 
- modulation of glycolytic enzymes, 
- reduction of ion channel fluxes, 
- suppression of neural activity, 
- expression of chaperones and heat shock proteins (Hsp), 
- activation of antioxidant defense systems, 
- adaptation of blood rheology and others.  
At first pass, the patient population that suffers from cerebral ischemic injury due to 
unpredictable focal stroke, cardiac arrest, or subarachnoid hemorrhage represents, by 
definition, one that is unlikely to derive benefit from preconditioning research. However, 
the novel endogenous survival pathways identified in preclinical IT studies may ultimately 
become targets for drugs that protect the brain even when acutely administered after the 
precipitating event. Importantly, a significant number of other patients—those in which we 
can anticipate a period of cerebral ischemia following transient ischemic attack, aneurysm 
clipping, subarachnoid hemorrhage, carotid endarterectomy or stenting, asymptomatic 
carotid stenosis, coronary bypass, and cardiac valve replacement—represent defined at-risk 
populations ideally suited for translational therapeutic preconditioning. The candidate 
drugs that might underpin clinical trials for this latter group of patients actually comprise a 
relatively long and therefore promising list, particularly if the current foundation of 
preclinical studies is expanded with intention. 
The concept of IPC in the heart was introduced in the late 80s by Murry et al. (1986) and 
later on in the brain by Schurr et al. (1986) and Kitagawa et al. (1991). Most stressors, 
including preischemia/hypoxia, induce both rapid and delayed tolerance phenotypes 
(Gidday, 2006). Mechanisms that are prominent during the first phases of acute ischemic 
insults such as excitoxicity are presumed to be induced during rapid IT. In particular, 
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elevation of adenosine and activation of adenosine receptor with the modulation of ATP 
sensitive K+ channel are paralleled by the activation of protein kinase C and other kinases in 
rapid tolerance. A critical role for nitric oxide signaling pathways in IPC and tolerance was 
also suggested (Nandagopal et al., 2001). As was recently shown by Meller et al. (2008), the 
selective ubiquitin–proteasome degradation of a cell death-associated protein, Bcl-2-
interacting mediator of cell death (Bim) with the reduced activation of programmed cell 
death-associated caspases (caspase 3) could play an important role in rapid tolerance to 
ischemia. As mentioned earlier, IT can be induced by various stimuli that are not necessarily 
ischemic or hypoxic.  
 
 
Fig. 1. Ischemic insult without any maneuvers leads to ischemic/reperfusion injured 
phenotype. Cerebroprotection can be induced by different types of preconditioning or 
postconditioning maneuvers/stimuli (ischemic, immunological, pharmacological and 
anesthetic). Temporary defined responses during therapeutical window may induce 
protective response with which subsequent ischemia serve as basis of the ischemic-tolerant 
phenotype. Adapted from Lehotsky et al. (2009b). 
Thus, the phenomenon of cross-tolerance implies that noxious stress can initiate cellular 
tolerance to subsequent stress that is different in nature from the first one. Therefore, one 
stressor can promote cross-tolerance to another; however, the efficacy of this tolerance may 
be more modest, and it appears to vary with the nature and intensity of the first challenge. 
Additionally, the window of evolved IT may also be shifted. However, the nature of the 
stimulus may determine the specific protective or in worse meaning the reduced damage 
epiphenotype. 
3. Prophylactic treatment with statins: Effect on ischemic damage 
Neuronal ischemic/reperfusion damage in the brain occurs rapidly. However, significant 
structural changes are observed over a course of hours or days in the form of delayed 
neuronal death. Interruption of blood flow initiates high-energy metabolism failure, ATP 
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depletion, ion imbalance, as well as other biochemical changes, such as an increase of free 
radicals, mitochondrial dysfunction, lactic acidosis, and inhibition of proteosynthesis as a 
consequence of endoplasmic reticular (ER) stress (DeGracia et al., 2002). 
The endoplasmic reticulum of eukaryotic cell reacts to ischemic injury by the unfolded 
protein response (UPR), which can be highly variable, depending on dosage and duration 
of ischemic treatment (Imaizumi et al., 2001), and intensity of UPR signals (Yoshida et al., 
2003). However, when ER stress is too severe and prolonged, apoptosis is induced. Various 
enzymes and transcription factors including the double-stranded RNA-activated protein 
kinase (PKR)-like ER kinase (PERK) (Harding et al., 1999), the transcription factors ATF4 
and ATF6 (activating transcription factor 6) and the inositol-requiring enzyme IRE1 (Shen et 
al., 2001) are involved in the UPR. In the physiological state, PERK, ATF6, and IRE1 activity 
is suppressed by binding of the ER chaperone: glucose regulated protein 78 (GRP78). 
Morimoto et al. (2007) reported that induction of GRP78 prevents neuronal damage induced 
by ER stress, and the increase in GRP78 (BiP) expression may correlate with the degree of 
neuroprotection.  
Statins, inhibitors of sterol synthesis, have been shown to reduce cerebrovascular events by 
their pleiotropic effects independent of the cholesterol lowering mechanism. Nagotani et al. 
(2005) found that simvastatin was the most effective statin against spontaneous stroke in 
human and animals. Strong liposolubility of statins may result in high permeability through 
the blood–brain barrier to the parenchyma, thereby protecting the neurons against ROS-
induced lipid peroxidation and DNA oxidation. The neuroprotective properties of 
simvastatin in experimental stroke have been evaluated by using several rodent-simulated 
models of cerebral ischemia (Shabanzadeh et al., 2005; Hayashi et al., 2005). As shown by 
previous studies, the changes of the UPR gene expression induced by transient ischemia 
occur mostly during the first 24 h (Paschen 2003b) or the first few days after the insult (Qi et 
al., 2004). In line with this, Urban et al. (2009) have decided to measure changes in mRNA 
and protein levels of GRP78, ATF6, and XBP1 after 15 min of global ischemia and 1, 3, and 
24 h reperfusion (UPR reaction). In addition, they have focused their attention on the effect 
of simvastatin pretreatment on the stress reaction of endoplasmic reticulum induced by 
ischemic/reperfusion insult. 
Adult male Wistar rats were used as animal model for the experiment. Global forebrain 
ischemia was induced by the standard four-vessel occlusion model (Lehotský et al., 2004; 
Sivonova et al., 2008; Uríkova et al., 2006). For maximal proof of changes in mRNA levels, 
authors used real-time PCR.  Cortexes from sham control, ischemic and simvastatin-treated 
animals were homogenized, and resolved by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and level of levels of ER stress gene proteins was analyzed by 
Western blotting after ischemic/ reperfusion damage (I/R) in naive rats and rats pretreated 
with simvastatin (20 mg/kg for 14 days). In the non-treated I/R animals, the mRNA level was 
significantly maximal in ischemic period (43 ± 3.2% in comparison to control), followed by 
rapid significant decrease from the first hour of reperfusion to a minimum value reached at the 
third hour (57 ± 7.8% lower than control). The mRNA level at 24 h of reperfusion reached 
control values. The level of XBP1 protein in non-treated animals showed only slight, not 
significant, differences compared to controls, mainly at later reperfusion periods (3 and 24 h).  
The influence of simvastatin on mRNA level was significant only in the first and the third 
hours of reperfusion compared to control I/R animals (about 32.8 ± 4.1% lower and two 
times higher in I3R, respectively). The changes in mRNA levels were not projected onto 
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protein levels, which, in contrast to control I/R animals, was found to be significantly lower 
(about 37.4 ± 2.2% in ischemic phase and about 36.3 ± 5.7% lower in first hour of 
reperfusion). In this paper, Urban et al (2009) were interested in finding whether global 
ischemia induced by four vessel occlusion followed by reperfusion at different time points 
would initiate the unfolded protein response of ER in cortical neurons. In addition, they 
have proved that prophylactic simvastatin therapy affects expression of gene coding for the 
main proteins involved in UPR.  
Clinical trials demonstrated that 3-hydroxy-3- methylglutaryl coenzyme A reductase 
inhibitors or statins exert beneficial effects when used as stroke prophylactic agents 
(Byington et al., 2001; Vaughan et al., 2001). These studies showed that statins reduce the 
incidence of both first and secondary events by 25– 30% and prevention is believed to be 
achieved mainly through their activity on blood vessel wall function. However, in addition 
to exerting anti-atherosclerotic and anti-thrombotic effects, statins also possess 
antiinflammatory and neuroprotective actions, which have been identified as cholesterol-
independent or pleiotropic effects (Vaughan and Delanty, 1999; Takemoto and Liao, 2001). 
The findings indicated that administration of simvastatin or other statins reduced the size of 
brain damage (Sironi et al., 2003; Amin-Hanjan et al., 2001). The beneficial effect of 
simvastatin is achieved only when the drug is administered before the ischemic insult; 
therefore, acting as a prophylactic agent (Balduini et al., 2003). In the model of focal 
ischemia induced by middle carotid artery occlusion (MCAO), the size of the damaged 
tissue increased by 47% after 24 h and by 83% after 48 h as compared to the infarct size 
detected at 2 h. This time-dependent enhancement of the damage was abolished in animals 
pre-treated with simvastatin, as the volume of infarct was never larger than the volume 
reported 2 h after MCAO. (Cimino et al., 2005). 
In general, I/R injury initiates suppression of global proteosynthesis (de la Vega et al., 2001; 
Paschen, 2003a). Ischemia is one of the strongest stimuli of gene induction in the brain. 
Different gene systems related to reperfusion processes of brain injury, repair, and recovery 
are up-regulated (Gidday, 2006). Focal ischemia shorter than 3,5 minutes and seven days of 
reperfusion usually causes degeneration of 75% of the neurons in the hippocampal CA1 region 
(Ohtsuki et al., 1996). On the other hand 6–10-minutes long global ischemia and three days of 
reperfusion caused death of almost all pyramidal neurons in the same hippocampal area 
(Coimbra and Wieloch, 1994). Urban et al., (2009) showed a significant increase of XBP1 
mRNA level in ischemic phase in comparison to control (about 43% more). These findings are 
similar to those observed by Paschen (2003a), which showed a marked increase in processed 
XBP1 mRNA levels using semi-quantitative RT-PCR after focal ischemia. These changes were 
most pronounced in the cerebral cortex, where high levels were found throughout the entire 
observation period. Urban et al (2009) obtained similar results; however, the differences were 
smaller probably due to the different ischemic model. The rapid increase of mRNA level of 
XBP1 along with other genes in ischemic phase of non-treated animals was probably due to 
forthcoming dissociation of protein GRP78, which reached a maximum at ischemic phase and 
first hour of reperfusion, from bounds with sensors of UPR which quickly (ATF6) or slowly 
(XBP1) started transcription of effector’s genes.  
In simvastatin-treated animals, rapid increase of mRNA in ischemic phase was mainly a 
consequence of transcription factor ATF6.  It has been proposed that the strong inhibition of 
translation induced after transient cerebral ischemia prevents the expression of key effector 
UPR proteins such as the XBP1, GRP78, or ATF4, thereby hindering recovery from ischemia-
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induced ER dysfunction (Kumar et al., 2001; Paschen, 2003a) and possibly leading to a pro 
apoptotic phenotype (De-Gracia and Montie, 2004). Similarly, in experiments of Urban et al. 
(2009), authors did not detected any significant changes in the protein level of XBP1 neither 
in ischemic period nor in the first 24 h of reperfusion. The results from measurements of 
XBP1 mRNA in simvastatin-treated animals did not show any significant changes in 
comparison to naive ischemic animals, i.e., the maximal differences were detected in the first 
and third hour of reperfusion (about 32.8 ± 4.1% lower in I1R and two times higher in I3R, 
respectively). A bit surprisingly, the protein level of XBP1 was generally decreased in pre-
treated animals (mainly in ischemic and I1R phase than non treated group), and did not 
reach control levels. Recently, a novel action of statins was proven in neurons, involving cell 
growth and signaling as well as down-regulation of proinflammatory gene expression 
attenuating neurogenic inflammation (Johnson-Anuna et al., 2005; Bucelli et al., 2008). 
The results of real-time PCR measurement showed an increased mRNA level of GRP78 in 
ischemic time and at later phases of reperfusion in non-treated animals. Probable reason is 
that GRP78 is a member of the 70-kDa heat shock protein family that acts as a molecular 
chaperone in the folding and assembly of newly synthesized proteins within the ER. Yu et 
al. (1999) reported that suppression of GRP78 expression enhanced apoptosis and disruption 
of cellular calcium homeostasis in hippocampal neurons exposed to excitotoxic and 
oxidative insults. This indicates that a raised level of GRP78 makes cells more resistant to 
the stressful conditions (Aoki et al., 2001). 
In experiments of Urban et al. (2009), authors did not find any significant changes in protein 
levels of GRP78 neither in simvastatin-treated nor in non-treated group of animals. They 
have just found maximum at third hour of reperfusion in statin group and small decrease at 
24 h of reperfusion in both groups. Those results are similar to the findings of Burda et al. 
(2003), who failed to find any differences in GRP78 protein levels at any of the reperfusion 
times considered (max 4 h), either in rats with or without acquired ischemic tolerance. 
However, in a model of ischemic preconditioning in rats (Hayashi et al., 2003; Garcıa et al., 
2004) an increase in GRP78 expression was detected after 2 days of preconditioning. Authors 
proposed that development of tolerance includes changes in PERK/GRP78 association, 
which were responsible for the decrease in eIF2a phosphorylation induced by 
preconditioning. Other studies using distinct ischemic models also failed to detect increased 
levels of GRP78 protein (Paschen 2003a). 
The results of Urban et al, (2009) also showed an increased mRNA expression of ATF6, 
however, only in ischemic time. Consequently levels of mRNA for GRP78 were increased 
only slightly compared to controls. The minimum level of mRNA for ATF6 was observed at 
third hour of reperfusion followed by increase till 24 h of reperfusion. This minimum was 
probably due to pro-survival mechanism through inhibition of proapoptotic protein 
GADD153, which usually acts as a transcription factor of UPR genes. GADD153 protein 
decreased during reperfusion, until the minimum was reached at the third hour of 
reperfusion (Kumar et al., 2003). Urban et al. (2009) also showed significant higher levels of 
ATF6 mRNA in statin-treated animals in comparison to non-statin animals at ischemic 
period and at third hour of reperfusion (about 35.2 ± 6.6% and 42 ± 2.6% higher level), which 
was also translated into the higher protein level, whose values had significant maximum at 
third hour of reperfusion (about 60% higher level than in non-treated animals).  
The experimental results altogether indicate that global ischemia/reperfusion initiates time-
dependent differences in endoplasmic reticular gene expression at both the mRNA and 
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protein levels and these authors also found  the generally enhanced level of mRNA in 
simvastatin pre-treated animals. The maximal differences between naive ischemic and pre-
treated ischemic animals authors detected in protein levels of proteins ATF6 and XBP1. The 
level of ATF6 was 60% higher in simvastatin pre-treated animals, which might suggest that 
ATF6 is one of the main proteins targeted to enhance neuroprotective effect at the ER gene 
level during first two hours of reperfusion.  
In conclusion, these data indicate that statins, in addition to their cholesterol-lowering effect 
may exert a neuroprotective role in the attenuation of ER stress response after acute 
ischemic/reperfusion insult.  
4. Impact of IRI and IPC on mitochondrial calcium transport, p53 
translocation and neuronal apoptosis 
Mitochondria are important regulators of neuronal cell life and death through their role in 
metabolic energy production and involvement in apoptosis (Yuan and Yanker, 2000). 
Remarkably, mitochondrial dysfunction is considered to be one of the key events linking 
ischemic/recirculation insult with neuronal cell death (Berridge et al., 2003). In addition, 
mitochondria play a dual role in intracellular calcium. They are involved in the normal 
control of neuronal Ca2+ homeostasis (Berridge et al., 2003), such as Ca2+ signaling, Ca2+ -
dependent exocytosis and stimulation of oxidative metabolism and ATP production 
(Rizzuto, 2001; Gunter et al., 2004).  
Conversely, mitochondrial Ca2+ overload and dysfunction, due to excitotoxic activation of 
glutamate receptors, is a crucial early event which follows ischemic or traumatic brain 
injury (Nicholls et al., 2007). Evidence for mitochondrial Ca2+ accumulation after 
excitotoxic stimulation comes from experimental studies which support the idea that 
mitochondrial depolarization during glutamate exposure is neuroprotective (Pivovarova 
et al., 2004), while its reduction correlates with excitotoxicity (Ward et al., 2007). In 
addition, activation of apoptosis has been documented after brain ischemia in several 
studies (Cao et al., 2003; Endo et al., 2006), and that this phenomenon might be closely 
linked to mitochondrial dysfunction. In fact, mitochondrial dysfunction provoked 
activation of apoptotic machinery by direct triggering of cytochrome c release (Clayton et 
al., 2005), or induction of Bax-dependent neuronal apoptosis through mitochondrial 
oxidative damage (Endo et al., 2006). 
Mitochondria are involved in the control of neuronal Ca2+ homeostasis and neuronal Ca2+ 
signaling. In a series of recent papers (Racay et al., 2007, 2009a,b,c), authors have studied the 
effect of global cerebral ischemia/reperfusion injury (IRI) and ischemic tolerance developed 
by prior ischemic non-injurious stimulus – preconditioning-  ischemic preconditioning (IPC) 
on mitochondrial Ca2+homeostasis and mitochondrial way of apoptosis. As documented by 
Racay et al. (2007, 2009a), global ischemia led to progressive decrease of complex I activity 
after IRI to 65.7% of control at 24 h after reperfusion. In preconditioned animals, the activity 
of complex I was also significantly inhibited after ischemia (to 65.4% of control) and 
ischemia/reperfusion for 1, 3, and 24 h (62-78% of control). Although the values in 
preconditioned animals were significantly smaller compared to naive ischemia, IPC did not 
protect complex I from ischemia induced inhibition. On the other hand, activity of the 
terminal enzyme complex of respiratory chain, complex IV were slightly protected by IPC 
and the net effect of IPC was the shift of its minimal activity from 1 h to 3 h after reperfusion 
(Racay et al., 2009c). 
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Mitochondrial dysfunction and oxidative stress were often implicated in pathophysiology of 
neurodegenerative diseases, including cerebral ischemia (Lin and Beal, 2006). Inhibition of 
complex I itself or in combination with elevated Ca2+ led to enhanced ROS production in 
different in vitro and in vivo systems (Yadava and Nicholls, 2007). Importantly, an enhanced 
production of ROS and consequent induction of p53-dependent apoptosis due to damage to 
neuronal DNA has also been documented after inhibition of complex I. A recent study 
showed that spare respiratory capacity rather then oxidative stress is involved in excitotoxic 
cell death (Yadava and Nicholls, 2007). 
As shown by experimental and clinical studies, IRI –induced mitochondrial pathway of 
apoptosis is an important event leading to neuronal cell death after blood flow arrest. 
Impact of IRI and ischemic preconditioning on the level of apoptotic and anti-apoptotic 
proteins was assessed in both cortical and hippocampal mitochondria by Western blot 
analysis of p53, bax, and bcl-x (Racay et al., 2007, 2009b). Remarkably, IRI led to increase of 
p53 level in hippocampal mitochondria, with significant differences after 3 h (217.1 ± 42.2% 
of control), 24 h (286.8 ± 65% of control), and 72 h (232.9 ± 37.3% of control) of reperfusion. 
Interestingly, translocation of p53 to mitochondria was observed in hippocampus but not in 
cerebral cortex. However, levels of both the apoptotic proteins bax and the anti-apoptotic 
bcl-xl were unchanged in both hippocampal and cortical mitochondria. Ischemia-induced 
translocation of p53 to mitochondria was completely abolished by IPC since no significant 
changes in mitochondrial p53 level were observed after preconditioned ischemia. Similar to 
naive ischemia, the levels of both bax and bcl-xl were not affected by IPC. In addition, IPC 
had significant protective effect on ischemia-induced DNA fragmentation, as well as on 
number of positive Fluoro-Jade C staining cells. Thus, it indicates that IPC abolished almost 
completely both initiation and execution of mitochondrial apoptosis induced by global brain 
ischemia in vulnerable CA1 layer of rat hippocampus (Racay et al., 2007, 2009b). 
The studies showed that ischemia induced inhibition of mitochondrial complexes I and IV, 
however inhibition is not accompanied by a decrease of mitochondrial Ca2+ uptake rate 
apparently due to the excess capacity of the complex I and complex IV. On the other hand, 
depressed activities of complex I and IV are conditions favourable of initiation of cell 
degenerative pathways, e.g. opening of mitochondrial permeability transition pore, ROS 
generation and apoptosis initiation, and might represent important mechanism of ischemic 
damage to neurons.  
Accordingly, ischemic preconditioning acts at the level of both initiation and execution of 
ischemia-induced mitochondrial apoptosis affording protection from ischemia associated 
changes in integrity of mitochondrial membranes. IPC also activates inhibition of p53 
translocation to mitochondria. Inhibition of the mitochondrial p53 pathway thus might 
provide a potentially important mechanism of neuronal survival in the face of ischemic 
brain damage (Otani, 2008). 
5. Stress reaction of neuronal endoplasmic reticulum after IRI and IPC 
Ischemic tolerance can be developed by prior ischemic non-injurious stimulus or 
preconditioning. The molecular mechanisms underlying ischemic tolerance are not yet fully 
understood yet. Therefore a series of papers (Urban et al., 2009; Lehotsky et al., 2009; 
Pavlikova et al.,2009) have focused attention at the mRNA and protein levels of the ER 
stress genes after ischemic/reperfusion damage (IRI) in naive and preconditioned groups 
of rats.  
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In the UPR response, an activated IRE1 specifically cuts out the coding region of X-box 
protein 1 (XBP1) mRNA (Calfon et al., 2002) which after translation functions as a 
transcription factor specific for ER stress genes including GRP78 and GRP94. In these 
experiments, the hippocampal mRNA for XBP1 showed elevated levels in the naive IRI 
group of animals during the ischemic phase (about 43% ) as well as persistent non-
significant changes in all other analyzed periods (Urban et al., 2009; Lehotsky et al., 2009).  
Preischemic treatment (IPC) induces the level of hippocampal mRNA in ischemic phase 
only slight but not significant differences compared to controls, followed by significant 
decreases at 24 hours of reperfusion (by about 12.8 ± 1.4% compared to controls). When 
analyzed the translational product, the hippocampal XBP1 protein level in naive IRI animal 
group showed significant differences in ischemic phase (39.2 ± 1.6% compared to controls) 
and the levels were significantly elevated at later reperfusion periods (3 and 24 h) (82 ± 2.4% 
and 24.1± 1.6% respectively compared to controls). The influence of preischemia (IPC) on 
protein levels was significant mainly in later ischemic times. The protein level reached a 
maximum at 3 h of reperfusion (about 230% of controls) and stayed elevated in the later 
reperfusion (40.3 ± 4.9% compared to controls) (Urban et al., 2009; Lehotsky et al., 2009).  
Endoplasmic reticular chaperone, the Ca2+ binding, glucose regulated protein 78 (GRP78) 
was shown to prevent neuronal damage (Morimoto et al., 2007). Under ER dysfunction and 
GRP78 dissociation it subsequently induced expression of ER stress genes. At the level of 
mRNA for GRP78 in hippocampus from naive IRI group of animals, the authors observed 
that maximal differences appeared in later reperfusion phases. Preischemic pretreatment 
(IPC) led to elevated mRNA hippocampal levels in the reperfusion period by about 11.7 ± 
3.6 during the first hour and by about 8.7± 1.8% the next 24 hours of reperfusion in 
comparison to mRNA levels in corresponding ischemic/reperfusion times. Remarkably, the 
level of GRP78 protein in naive IRI showed rapid increases in ischemic time (by about 217% 
of controls) and remained elevated throughout 3 to 24 hours of reperfusion (about 213% and 
43%, respectively, compared to controls). Increased mRNA values in preconditioned 
animals also corresponded with the significant increase of the levels of GRP78 protein. The 
changes are documented in the ischemic phase and also in all reperfusion times (by about 
250% of controls and about 50% of corresponding ischemic/reperfusion times) (Urban et al., 
2009; Lehotsky et al., 2009).  
ATF6 works as a key transcription factor in the resolution of the mammalian UPR (Yoshida 
et al. 2001). As shown in this experiment, the mRNA level for ATF6 in naive IRI animals 
showed gradual significant increases up to 24 hours of reperfusion (9.2 ± 4 % higher than 
control) and preconditioning (IPC) did not significantly alter mRNA levels in all analyzed 
periods. Similarl to mRNA levels, the hippocampal ATF6 protein level in naive IRI animals 
followed the same patterns. IPC on the other hand, induced remarkable changes in the 
protein levels at ischemic phase achieving significant  increased levels (about 170%) in 
comparison to controls and stayed elevated in earlier reperfusion times (about 37 and 62 % 
higher than in controls) and later reperfusion time (about 15% of controls).  
In general, IRI initiates suppression of global proteosynthesis, which is practically recovered 
in the reperfusion period with the exception of the most vulnerable neurons, such as 
pyramidal cells of CA1 hippocampal region (de la Vega et al., 2001). Ischemia is one of the 
strongest stimuli of gene induction in the brain. Different gene systems related to 
reperfusion processes of brain injury, repair and recovery are modulated (Gidday, 2006). In 
fact, IRI induces transient inhibition of translation, which prevents the expression of UPR 
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proteins and hinders recovery from ischemia-induced ER dysfunction (Kumar et al., 2001; 
Paschen et al., 2003a) which possibly leads to a pro-apoptotic phenotype (DeGracia and 
Montie, 2004). Similarly, Thuerauf et al. (2006) found that myocardial ischemia activates 
UPR with the increased expression of XBP1 protein and XBP1-inducible protein. They 
contribute to protection of the myocardium during hypoxia. Also the results of Paschen et 
al. (2003a) using semi-quantitative RT-PCR showed a marked increase in XBP1 mRNA 
levels after focal ischemia in the cerebral cortex.  
Preischemia induced elevation of mRNA and protein GRP78 levels in reperfusion periods. 
GRP78 is a member of the 70kDa heat shock protein family that acts as a molecular 
chaperone in the folding and assembly of newly synthesized proteins within the ER. As 
shown by Yu et al. (1999) the suppression of GRP78 expression enhances apoptosis and 
disruption of cellular calcium homeostasis in hippocampal neurons that are exposed to 
excitotoxic and oxidative insults. This indicates that a raised level of GRP78 makes cells 
more resistant to the stressful conditions (Aoki et al. 2001). Similar results were obtained by 
Morimoto et al. (2007) in the focal ischemia model. Also Hayashi et al. (2003) and Garcia et 
al. (2004), who demonstrated an increase in GRP78 expression after 2 days of 
preconditioning proposed that the development of tolerance includes changes in 
PERK/GRP78 association, which were responsible for the decrease in eIF2a phosphorylation 
induced by preconditioning. On the other hand, Burda et al. (2003), failed to find any 
differences in the level of GRP78 protein in rats with or without acquired ischemic tolerance. 
This was probably due to exposure to very short reperfusion times. ATF6 is an ER-
membrane-bound transcription factor activated by ER stress, which is specialized in the 
regulation of ER quality control proteins (Adachi et al., 2008). Haze et al. (1999) found that 
the overexpression of full-length ATF6 activates transcription of the GRP78 gene. 
Explanation of generally higher levels of protein p90ATF6 in preischemic group is probably 
connected to an increased promotor activity of GADD153 to UPR genes (Oyadomari et al., 
2004).  
The data from these experiments (Urban et al. 2009; Lehotsky et al. 2009) suggest that IRI 
initiates time dependent differences in endoplasmic reticular gene expression at both the 
mRNA and protein levels and that endoplasmic gene expression is affected by preischemic 
treatment. These data and recent experiments of Bickler et al. (2009) also suggest that 
preconditioning paradigm (preischemia) may exert a role in the attenuation of ER stress 
response and that InsP3 receptor mediated Ca2+ signaling is an important mediator in the 
neuroprotective phenomenon of acquired ischemic tolerance. Changes in gene expression of 
the key proteins provide an insight into ER stress pathways. It also might suggest possible 
targets of future therapeutic interventions to enhance recovery after stroke (Yenari et al., 
2008; Pignataro et al., 2009). 
6. Effect of ischemic preconditioning on secretory pathways Ca
2+
-ATPase 
gene expression 
The Golgi apparatus, as a part of secretory pathways (SP) in neural cells, represents a 
dynamic Ca2+ store. Ca2+ ions play an active role in processes such as secretion of 
neurotransmitters and secretory proteins for the growth/ reorganization of neuronal 
circuits, synaptic transmission, neural plasticity, and remodeling of dendrites (Michelangeli 
et al., 2005). In addition, SP are involved in the stress sensing, neuronal aging, and 
transduction of apoptotic signals (Maag et al., 2003; Sepulveda et al., 2008). On the other 
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hand, a high luminal Ca2+ concentration, and Mn2+, is required in the Golgi apparatus for 
the optimal activity of many enzymes and for post-translational processing and trafficking 
of the newly formed proteins. For both cytosolic and Golgi Ca2+ and Mn2+homeostasis, the 
secretory pathway Ca2+-ATPases (SPCAs) play an important role.  
The SPCAs represent a subfamily of P-type ATPases related to the sarco(endo)plasmic 
reticulum Ca2+-ATPase (SERCA) and the plasma-membrane Ca2+-ATPase (PMCA) (Van 
Baelen et al., 2004; Murin et al., 2006). Two isoforms sharing 64% of sequence identity, 
namely SPCA1 and SPCA2, are expressed in mammalian cells (Wootton et al., 2004; Xiang et 
al., 2005). While SPCA2 expression seems to be more restricted to specific cell types, the 
SPCA1 is considered as a house-keeping isoform with pronounced expression in neural cells 
(Wootton et al., 2004; Murin et al., 2006; Sepulveda et al., 2008). The higher expression levels 
of SPCA1 in the brain coincide with a relatively high ratio of SPCA activity (thapsigargin 
insensitive) to the total activity of Ca2+-dependent ATPases. Therefore, implying a 
significant role of SPCA-facilitated transport of Ca2+ for calcium storage within the brain 
(Wootton et al., 2004). 
As shown by previous studies, the SPCA plays a pivotal role in normal neural development, 
neural migration, and morphogenesis (Sepulveda et al., 2007, 2008). In addition, as shown in 
SPCA1 knockout mice, SPCA1 deficiency caused alteration in neural tube development and 
Golgi stress. These animals presented structural changes in the Golgi such as dilatation and 
the reduction in the number of stacked leaflets (Okunade et al., 2007). In apoptosis, a 
morphological change in the Golgi complex, for example its fragmentation, represents an 
early causative step rather than a secondary event, and it is very commonly associated with 
several neurodegenerative diseases, such as amyotrophic lateral sclerosis, corticobasal 
degeneration, Alzheimer’s and Creutzfeldt-Jacob diseases, and spinocerebelar ataxia type 2 
(Gonatas et al., 2006). 
6.1 Effect of oxidative damage on SPCA1  
Collective studies confirm that reactive oxygen species contribute to neuronal cell injuries 
secondary to ischemia and reperfusion (Lehotsky et al., 2004; Burda et al., 2005; Danielisova 
et al., 2005; Shi and Liu, 2007). Oxidative burst lasting several minutes upon the onset of 
reperfusion is followed by dysregulation of antioxidant mechanism and moderate but 
persistently elevated production of oxygen radicals which might initiate cell death signaling 
pathways after cerebral ischemia and parallels with selective postischemic vulnerability of 
the brain (Valko et al., 2007; Shi and Liu, 2007). 
One of the main aims of the study of  Pavlikova et al. (2009) was to determine whether IRI 
and IPC would affect the physical and functional properties of hippocampal membrane 
vesicles including Golgi SP. Neuronal microsomes are vulnerable to physical and functional 
oxidative damage (Lehotsky et al. 1999, 2002a; Urikova et al. 2006). The nature of the effect 
of free radicals on SPCA1 protein is not yet known. Authors show here for the first time that 
SPCA activity is also selectively damaged by free radicals in vitro, the property which is 
similar to other P-type ATPase such as SERCA and PMCA (Lehotsky et al. 2002b). In the 
study, authors showed that transient ischemia for 15 min induces considerable LPO and 
protein oxidation in hippocampal membranes. Protein oxidation pursues disturbances in 
oxidant/antioxidant balance and depression of enzymatic activities of main antioxidant 
enzymes detected at later stages after the ischemic insult (Lehotsky et al., 2002a; Urıkova et 
al., 2006). Thus, oxidative alterations detected after IRI may at least partially explain 
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functional post-ischemic disturbances of neuronal ion transport mechanisms (Lipton, 1999; 
Lehotsky et al., 2002a; Obrenovitch, 2008) and inhibition of global proteosynthesis (Burda et 
al., 2003), which both are implicated in neuronal cell damage and/or recovery from ischemic 
insult. 
IPC caused significant reductions of LPO products and it reduced protein oxidative changes 
induced by ischemia in the hippocampal membranes in both the ischemic time and in 
reperfusion period. One of the possible explanations comes from the studies describing 
upregulation of defense mechanisms (antioxidant enzymes) against oxidative stress due to 
the preconditioning challenge (Danielisova et al., 2005; Gidday, 2006; Obrenovitch, 2008). In 
addition, forebrain ischemia causes small but significant drops in the SPCA-associated 
Ca2+-ATPase activity (by about 9%). The activity increases in early reperfusion times. 
However, it did not reach the control level and reached the highest depression after 24 h 
reperfusion to 88% of control. In the experiments, the IPC had a partial protective effect on 
the SPCA-associated Ca2+-ATPase activity. Ischemic insult after IPC pretreatment initiate 
only non-significant inhibition of Ca2+-ATPase activity compared to preconditioned control. 
After 1 and 3 h of reperfusion, the activity exceeded the control levels and reached it again 
after 24 h of reperfusion. However, the changes were not statistically significant at any 
reperfusion time. As shown in earlier studies, preconditioning upregulates defense 
mechanisms against oxidative stress (Danielisova et al., 2005; Gidday, 2006; Obrenovitch, 
2008), which might partially restore the depression of enzyme activity. Additionally, as 
shown in the study by Western blot analysis, IPC induced an elevation of SPCA protein 
level in comparison to corresponding naive ischemic control. 
In summary, the experiments conclusively showed that cerebral IRI-induced depression of 
SPCA activity and lipid and protein oxidation in rat hippocampal membranes. IRI also 
activates induction of SPCA1 gene expression in later reperfusion periods. IPC partially 
suppresses oxidative changes in hippocampal membranes and also partially restores the 
ischemic-induced depression of SPCA activity.  
In addition, IPC initiates earlier cellular response to the injury by the significant elevation of 
mRNA expression (to 142% comparing to 1 h of corresponding reperfusion) and to 154 and 
111% comparing to 3 and 24 h of corresponding reperfusion, respectively. Similar patterns 
were observed on the translational level by Western blot analysis. Results of Pavlikova et al. 
(2009) indicate the specific SPCA1 expression pattern in injured ischemic hippocampus and 
might serve to understand the molecular mechanisms involved in the structural integrity 
and function of the Golgi complex after ischemic challenge. They also suggest for the 
correlation of SPCA function with the role of SP in response to preischemic challenge. 
Collective studies confirm, that reactive oxygen species (ROS) contribute to neuronal cell 
injuries secondary to ischemia and reperfusion (Lehotsky et al., 2004; Burda et al., 2005; 
Danielisova et al., 2005; Shi and Liu, 2007) and might initiate cell death signaling pathways 
after cerebral ischemia and parallels with selective post-ischemic vulnerability of the brain 
(Valko et al., 2007; Shi and Liu, 2007; Otani, 2008; Dirnagl et al., 2009). As shown by 
measurement of steady state fluorescence of ANS in hippocampal mitochondria (Racay et 
al., 2007, 2009a), naive IRI induced significant increase in ANS flurescence (it binds to 
hydrophobic part of membrane lipids and proteins) of the forebrain  in both ischemic and 
reperfusion periods. These results support data from previous experiments (Lehotsky et al., 
2004; Babusikova et al., 2008), which showed that IRI induced structural changes on 
hippocampal membrane lipids and both, the lipoperoxidation dependent and the direct 
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oxidative modifications of membrane proteins. Remarkably, preconditioning (IPC) induces 
significant decrease of ANS fluorescence, which indicates protective effect of IPC on 
mitochondrial membranes. 
SP are involved in the stress sensing, neuronal aging and transduction of apoptotic signals 
(Maag et al., 2003; Sepulveda et al., 2008). In order to evaluate whether the severe metabolic 
stress induced by IRI and/or IPC affects transcription of SPCA1 gene, the mRNA and 
protein levels of SPCA1 was analyzed (Lehotsky, 1999, 2002a, 2004). As shown by Pavlikova 
et al. (2009), RT-PCR clearly detected, that hippocampal cells respond to the IRI by induction 
of mRNA level in reperfusion period with maximum at 3 h reperfusion (to 171% of control). 
Preconditioning (IPC) initiates earlier tissue response to the injury by the significant 
elevation of mRNA expression already at 1 h of reperfusion and the level of mRNA 
expression reached 142% comparing to 1 h ischemia, and to 164% comparing to control. 
Neuronal microsomes are vulnerable to physical and functional oxidative damage 
(Lehotsky et al., 1999, 2002a, 2004; Urikova et al., 2006). The authors showed (Pavlikova et al. 
(2009) that SPCA activity, similar to other P-type ATPases, is also subject to ischemic 
damage most likely due to free radicals action (Lehotsky et al., 2002b). In addition, oxidative 
alterations detected in mitochondria and microsomes after IRI in our experiments, may at 
least partially explain functional postischemic disturbances of neuronal ion transport 
mechanisms (Lipton 1999; Lehotsky et al., 2002a; Obrenovitch, 2008) and inhibition of global 
proteosynthesis (Burda et al., 2003), which are both implicated in neuronal cell damage 
and/or recovery from ischemic insult, IPC-induced reduction of lipoperoxidation products 
and protein oxidative changes (Racay et al., 2009; Pavlikova et al., 2009). These may all be 
probably due to upregulation of defence mechanisms (antioxidant enzymes) against 
oxidative stress in the preconditioning challenge (Danielisova et al., 2005; Gidday, 2006; 
Obrenovitch, 2008).  
One of the most pronounced morphological features following IRI is the mitochondrial and 
Golgi swelling and activation, which could be suppressed by neuroprotective treatment 
(Hicks and Machaner, 2005; Strosznajder et al., 2005; Gonatas et al., 2006). The secretory 
pathways are apparently involved in sensing stress and transducing signals during the 
execution phase of apoptosis (Maag et al., 2003; Hicks and Machamer, 2005). Data from 
Pavlikova (2009) showed a partial recovery of Ca2+-ATPase activity and earlier hippocampal 
response to later ischemia by the induction of mRNA and protein expression. 
Cross-talk between the function of intracellular organelles following ischemic insult and 
reperfusion (Fig.2) and response of the tissue to the preischemic challenge (Fig 3) is depicted 
bellow .   
6.2 Effect of hyperhomocysteinemia on SPCA expression  
Homocysteine (Hcy) is a sulfur-containing amino acid, which is derived from methionine 
metabolism. Hyperhomocysteinemia, condition in which Hcy concentration exceeds 16 
µmol/l, is the result of perturbed Hcy metabolism and dietary deficiencies in folic acid, 
vitamin B6, and/or vitamin B12 (Obeid et al., 2007).  
Hyperhomocysteinemia has been implicated as an independent risk factor for 
arteriosclerosis and coronary heart disease (Refsum et al., 1998; Thambyrajah et al., 2000). 
Severe forms of hyperhomocysteinemia results in convulsions and dementia (Watkins et al., 
1989; van den Berg et al., 1995) corresponding multiple participation of homocysteine (Hcy) 
in diverse pathologies that affect the CNS. Likewise, homocysteine has also been associated 
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with several CNS disorders, such as stroke (Obeid et al., 2007), epilepsy (Sachdev, 2004; 
Herrmann et al., 2007), neurodegenerative (Clarke et al., 1998; Mattson et al., 2002) and 
neuropsychiatric diseases (Diaz-Arrastia, 2000; Bottiglieri, 2005), as well as inborn errors of 
metabolism (Mudd et al., 2001). In addition, even moderate hyperhomocysteinemia is a 
factor stimulating the development of dementia and Alzheimer’s disease (Seshadri et al., 
2002). 
 
 
Fig. 2. Cross-talk between the fuction of intracellular organelles which follows ischemic 
insults and results in injured phenopyte  in vulnerable neurons. Adapted from Lehotsky et 
al. (2009c). 
Ischemic brain stroke in humans represents very complex cerebrovascular disease. A 
number of conventional risk factors for ischemic stroke are known, such as a previous 
occurrence of stroke, previous transient ischemic attack (TIA), arterial disease, atrial 
fibrillation, poor diet and/or obesity and physical inactivity (Prasad, 1999). It has been 
reported that hyperhomocysteinemia may also be associated with the incidence of ischemic 
brain stroke (Refsum et al., 1998), mainly due to pleiotropic activity of homocysteine and 
acceleration of atherosclerotic changes (Refsum et al., 1998; Thambyrajah et al., 2000). In fact, 
Hcy suppresses NO production by endothelial cells (Upchurch et al., 1997) and platelets 
(Mutus et al., 2001) and increases generation of reactive oxygen species (ROS) by the release 
of arachidonic acid from platelets (Signorello et al. 2002). It also inhibits glutathione 
peroxidase (Upchurch et al., 1997), and thus stimulates proliferation of endothelial cells 
(Jeremy et al., 1999; Domagala et al., 1998).  
In addition, Hcy has been shown to inhibit methyltransferases, to suppress DNA reparation 
and to facilitate apoptosis when accumulated inside the cells (Duan et al., 2002; Kruman et 
al., 2002). Autooxidation of Hcy metabolites results in H202 accumulation  (Gortz et al., 2004; 
Boldyrev, 2005) and long term incubation of neurons with Hcy metabolites induces necrotic 
cell death (Zieminska et al., 2003; Boldyrev et al., 2004). Homocysteine has also been shown 
to be elevated in other disorders of the CNS, e.g. Alzheimer disease or Parkinson disease 
(Toohey, 2007). 
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A series of papers (Urban et al., 2009; Lehotsky et al., 2009b; Pavlikova et al.,2009) found that 
ischemia/reperfusion injury (IRI) initiates time dependent differences in endoplasmic 
reticular gene expression at both the mRNA and protein levels in rat hippocampus and that 
endoplasmic gene expression is affected by pre-ischemic treatment. More recently, 
Pavlikova et al. (2011) conducted an investigation into the differences between naive control 
and hyperhomocysteinemic control animals in each group independently. They showed for 
the first time that experimental 2 weeks hyperhomocysteinemia significantly decreased the 
level of SPCA1 mRNA gene expression in cerebral cortex which also led to the non-
significantly decreased expression levels in hippocampal area. In cortex, ischemic challenge 
for 15 min. did not change significantly the level of mRNA SPCA1 expression in comparison 
to controls. Conversely, the gene response to pre-ischemic challenge was clearly shown 
within the homocysteine group by abrupt stimulation of the mRNA expression level to 249 
% of hyperhomocysteinemic ischemic group and to 321% of hyperhomocysteinemic control. 
Notably, values far exceed those observed in the naive control. However, the effect of IPC 
challenge was not observed in the naive groups. 
 
 
Fig. 3. Cross-talk between the fuction of intracellular organelles which follow preischemic 
maneuver and  results in tolerant phenopyte  in vulnerable neurons. Adapted from 
Lehotsky et al. (2009c). 
The expression level decreased in the hyperhomocysteinemic control to 259% (p<0.05) of 
naive control and to 277% of control with IPC. When changes were compared between all 
ischemic groups, the following were observed: low level of mRNA expression in 
hyperhomocysteinemic ischemic group (to 201% of naive ischemia and to 185% of ischemic 
preconditioning. However, there were no significant differences between Hcy-control group 
and Hcy- ischemic group. Preischemic challenge initiated stimulation of the mRNA 
expression to 249% of hyperhomocysteinemic ischemic group. This response may be 
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attributed to a part of the protective tolerant phenomenon induced by preconditioning 
treatment.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Comparison of mRNA levels of SPCA1 between naive group (C-nai, Isch-nai), IPC 
group (C-IPC, Isch-IPC) and hyperhomocysteinemic group (C-Hcy, Isch-Hcy, Isch-IPC-Hcy) 
in rat cortex. Results are presented as mean ± SEM for n = 6. * p < 0.05 compared to C-nai 
group, + p < 0.05 compared to C-IPC groups, † p < 0.05 compared to Isch-Hcy group, ‡ p < 
0.05 compared to C-IPC group, ## p < 0.01 compared to Isch-IPC-Hcy group, && p < 0.01 
compared to Isch-IPC-Hcy group. C-nai, control naive group; Isch-nai, ischemia naive 
group, C-IPC, control preischemic group; Isch-IPC, preischemic group; C-Hcy, control Hcy 
group; Isch-Hcy, ischemia Hcy group; Isch-IPC-Hcy, preischemic Hcy group. Adapted from 
Pavlikova et al. (2011).   
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In results of mRNA SPCA1 expression in hippocampal area no statistically significant 
changes were found between naive control and IPC control groups. Hyperhomocysteinemia 
for 14 days supressed mRNA expression, however the changes were not statistically 
significant. Similarly, as shown in the cortex, the preischemic challenge in hippocampal 
region initiated stimulation of the mRNA expression by 159% of hyperhomocysteinemic 
control and by to 131% hyperhomocysteinemic ischemic group. The suggestion was, that 
this response might also be part of the protective tolerant phenomenon induced by 
preconditioning treatment.  
The previous results showed that IRI insult alters time expression profile of SPCA1 on 
mRNA and protein level (Pavlikova et al. 2009), and that preischemic challenge (induction 
of tolerance), not only preserved majority of surviving neuron but also activates partial 
recovery of the secretory pathways SPCA Ca2+-ATPase activity and earlier hippocampal 
response to later ischemia by the induction of  SPCA1 mRNA and protein expression. We 
shown here for the first time that chemically induced experimental 2 weeks 
hyperhomocysteinemia significantly decreased the level of SPCA1 mRNA gene expression 
in cerebral cortex and also led to the non-significant decreased expression level in 
hippocampal area. There are no literature data on how the Hcy might affect the expression 
profile of the Ca2+-transport proteins in neuronal cells. In fact, the general mechanism of 
transcriptional regulation of SPCA1 gene is not yet fully understood. The transcription 
factors Sp1 and YY1 were shown to be involved in the gene regulation by the cis-enhancing 
elements in 5´-untranslated regions (Kawada et al., 2005). Another possibility is the 
expression of the putative endogenous activator of SPCA or the changes in local membrane 
environment are suggested as a cause for the increase in SPCA activity (Sepulveda et al. 
2008). In fact, hyperhomocysteinemia often results in intracellular Ca2+ mobilization, 
endoplasmic reticulum (ER) stress, with the subsequent development of apoptotic events, 
chronic inflammation leading to endothelial dysfunction and remodeling of the extracellular 
matrix. Homocysteine has also been reported to induce modulation of gene expression 
through alteration of the methylation status (Dionisio, 2010). 
In conclusion, our results indicate that chemically induced hyperhomocysteinemia initiates 
supression of the SPCA1 gene expression in both brain regions cerebral cortex and 
hippocampus. Documented response of SPCA gene to preischemic challenge in 
hyperhomocysteinemic group of animals might suggest for the correlation of SPCA 
expression with the role of secretory pathways in the proposed phenomenon of ischemic 
tolerance (Dirnagl et al., 2009; Pignataro et al., 2009). This might also serve to understand the 
molecular mechanisms involved in the structural integrity and function of the Golgi 
complex after ischemic challenge. 
7. Conclusion  
Ischemic induced alterations of mitochondria, endoplasmic reticulum and Golgi apparatus 
shed more light on understanding the cross-talk between intracellular Ca2+ stores in cerebral 
ischemia/reperfusion injury. Documented neuroprotective response of intracellular 
organelles in the phenomenon of ischemic tolerance may also form a basis for future 
therapeutic interventions to enhance recovery from stroke. Finally, exploration of the 
protective mechanisms could lead to the recognition of newer strategies and suggestions for 
development of novel prophylactic/therapeutics for neuronal apoptosis-related diseases. 
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